Assessing Drug Penetration in Tumors
Author Information
Author(s): RM Phillips, PM Loadman, BP Cronin
Primary Institution: University of Bradford
Hypothesis
The study aims to evaluate the ability of various drugs to penetrate multicell layers in tumors.
Conclusion
The study found that poor drug penetration and rapid elimination in vivo contribute to the clinical failure of E09.
Supporting Evidence
- E09 does not penetrate multicell layers effectively, which may explain its poor clinical outcomes.
- Tirapazamine penetrates multicell layers more rapidly than doxorubicin.
- Reducing oxygen tension decreases the rate of drug penetration.
- Inclusion of dicoumarol increases the rate of E09 penetration.
Takeaway
This study looks at how well cancer drugs can get into the hard-to-reach parts of tumors, which is important for making them work better.
Methodology
DLD-1 human colon carcinoma cells were cultured on Transwell-COL plastic inserts, and drug penetration was assessed using high-performance liquid chromatography (HPLC).
Limitations
The study primarily focuses on in vitro conditions, which may not fully replicate in vivo tumor environments.
Want to read the original?
Access the complete publication on the publisher's website